A Life Sciences Location Analysis: Biopharma by the Numbers

This report breaks down how life sciences companies are evaluating locations today. It focuses on risk, infrastructure, and long-term viability—not just cost. Download the full report to explore: Why site selection is now a risk decision, not a cost comparison How talent concentration (nearly 6x the national average) impacts hiring and timelines What “research continuity” looks like and how it supports long-term innovation The role of GMP experience and regulatory fluency in scaling operations How infrastructure, water, and utilities affect advanced manufacturing readiness Why proximity to 40% of the U.S. market changes distribution strategy How cluster density reduces vendor friction and speeds execution What separates Middlesex County, NJ, from other major life sciences hubs

Share the Post:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to our use of all cookies, however, you may visit “Cookies Setting” to provide a controlled consent.

Privacy Policy